TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04129346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Coaching Calls
Description: Participants will receive weekly calls that will cover health and well-being topics for instance: symptom and stress management, healthy diet, hydration, sun safety, sleep hygiene, and meditation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cancer.net app
Description: Cancer.net app content includes information about health and well-being, treatment guidelines specific to cancer type, symptom tracking and medication tracking
Study: NCT01093053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups
Description: The mind-body skills group program teaches participants how to do meditation, guided imagery, breathing techniques, and biofeedback. These mind-body techniques are taught and practiced in small groups of 8 to 10 people and also contain an element of social support.
Study: NCT00709592

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT01093053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: May include individual or group psychotherapy consisting of cognitive behavioral therapy or present-centered (i.e. unrelated to mindfulness) psychotherapy as well as medication management. Medications for depression, anxiety, and sleep disorders are the most commonly used in standard treatment.
Study: NCT03877692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental dosing of labetalol
Description: Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive the experimental dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard dosing of labetalol
Description: Subjects with preexisting hypertension who have sustained severe hypertension (SBP≥160 mmHg and/or DBP≥110 mmHg), 15 min apart receive either the standard of care dosing of labetolol. Subjects in both groups are managed following the standard guidelines established by ACOG (Committee Opinion #623). For each successive episode of hypertension treatment, patients are asked a set of questions to monitor for adverse medication side-effects. The fetus is electronically monitored for four hours after the last IV dose.
Study: NCT03086460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1531 pMDI
Description: Dose Response: Test one of five different doses of CHF 1531
Study: NCT00709592

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT03086460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1531 pMDI
Description: Dose Response: Test one of five different doses of CHF 1531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1531 pMDI
Description: Dose Response: Test one of five different doses of CHF 1531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 1531 pMDI
Description: Dose Response: Test one of five different doses of CHF 1531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Inhalation Solution
Description: Active Control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pMDI
Description: Matched Placebo
Study: NCT03647293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Central Catheter Insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peripherally Inserted Central Catheter
Study: NCT00905528

Intervention type: DRUG
Intervention: Telmisartan 80 mg/d

Intervention type: DRUG
Intervention: Ramipril 10 mg/d
Study: NCT04229225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular (IA) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular (IA) injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intra-articular (IA) injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intra-articular (IA) injection
Study: NCT00283608

Intervention type: GENETIC
Intervention: Single nucleotide polymorphism (SNP)
Description: Evaluating SNP association with traits.

Intervention type: GENETIC
Intervention: Single nucleotide polymorphism (SNP)
Description: Evaluating SNP association with traits.
Study: NCT00709592

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic PBSCT or BMT
Description: Undergo allogeneic PBSCT or BMT
Study: NCT00283608

Intervention type: OTHER
Intervention: high performance liquid chromatography
Description: analysis of plasma concentrations of drugs
Study: NCT01786109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
Study: NCT00283608

Intervention type: OTHER
Intervention: high performance liquid chromatography
Description: analysis of plasma concentrations of drugs

Intervention type: OTHER
Intervention: measurements by DXA
Description: determine bone mineral density (BMD)

Intervention type: OTHER
Intervention: measurements by DXA
Description: determine bone mineral density (BMD)

Intervention type: OTHER
Intervention: questionnaire administration
Description: determine attitude changes
Study: NCT00283608

Intervention type: OTHER
Intervention: questionnaire administration
Description: determine attitude changes
Study: NCT02844660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EpiCord
Description: Weekly application of EpiCord and standard of care (moist wound therapy and offloading)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: moist wound therapy and offloading
Study: NCT03615105

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hyperfractionated total body irradiation
Description: Hyperfractionated TBI is administered by a linear accelerator at a dose rate of \<20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1,375 or 1,500 cGy) over 4 days (days -9 through -6).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 5 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa 5 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (adult/ped dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine 20-30 mg/m2 IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPC(A) stem cell allograft
Description: All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPC(A) stem cell allograft
Description: All patients will receive anti-thymocyte globulin based conditioning followed by a G-CSF mobilized, peripheral blood hematopoietic progenitor cell HPC(A) product depleted of TCR-α/β+ Tlymphocytes using the CliniMACS system.
Study: NCT03004846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle ointment
Description: It will be supplied as white to off-white vehicle ointment for topical application.
Study: NCT03035812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alkali
Description: Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
Study: NCT04609384

Intervention type: DEVICE
Intervention: Alcohol rub timer device
Description: A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence

Intervention type: DEVICE
Intervention: Alcohol rub timer device
Description: A device that should help the surgeon to increase the time spend on surgical rub. Further detail cannot be described due to confidence
Study: NCT01786109

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match study drug; taken as one dose orally with water.
Study: NCT03705611

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV self-testing only
Description: Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV self-testing only
Description: Partners will be asked to self-test for HIV following receipt of the test kit from their sexual contact at home or in the community. They will also get information about the partner's clinic -- an HIV testing service room dedicated to providing HIV testing, confirmatory HIV testing, and referral to HIV treatment and prevention services including couples counselling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV self-testing secondary accuracy
Description: A monetary incentive provided conditional on clinic attendance and fulfillment of secondary accuracy procedures such as undergoing on spot finger prick rapid HIV testing
Study: NCT03428204

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Balloon dilation during 180 seconds
Description: Percutaneous angioplasty with balloon dilation during 180 seconds as a method for percutaneous treatment of femoropopliteal artery lesions

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Balloon dilation during 300 seconds
Description: Percutaneous angioplasty with balloon dilation during 300 seconds as a method for percutaneous treatment of femoropopliteal artery lesions
Study: NCT06059079

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT03850587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: comparator medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol 37.5Mg+ Celecoxib 200mg
Description: experimental medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol 75mg+ Celecoxib 200mg
Description: experimental medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol 150mg+ Celecoxib 200mg
Description: experimental medication
Study: NCT03447795

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Alveolar ridge preservation
Description: grafting procedure using autogenous tooth.
Study: NCT00942682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Taken orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken orally once daily in the morning
Study: NCT01499576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acetic acid chromoendoscopy
Description: Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
Study: NCT01670500

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: administered intravenously every 3 weeks for 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
Study: NCT04246047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Proteasome Inhibitor
Study: NCT03447795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Alveolar ridge preservation
Description: grafting procedure using autogenous tooth.
Study: NCT03363035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg
Description: One 2.5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg
Description: One 5 mg rivaroxaban tablet twice daily until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 1mg/kg twice daily SC until hospital discharge or 12 hours before revascularization therapy for a maximum of 8 days.
Study: NCT04246047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Proteasome Inhibitor
Study: NCT01656746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic laparoscopic surgery
Description: Undergo single incision laparoscopic surgery
Study: NCT02729168

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human rabies vaccine
Study: NCT04246047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Synthetic glucocorticoid with anti-tumor activity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Synthetic glucocorticoid with anti-tumor activity
Study: NCT02722135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volasertib
Study: NCT03219736

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care therapies
Description: If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NiPPV Therapy
Description: If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Respiratory Care
Description: It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine Respiratory Care
Description: It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
Study: NCT01166334

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WebQuit study group
Description: Description withheld to protect integrity of study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WebQuit control group
Description: Identity and description withheld to protect integrity of study
Study: NCT02524678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: URC102
Study: NCT02086045

Intervention type: DEVICE
Group type: OTHER
Intervention: DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System
Description: percutaneous coronary
Study: NCT01370538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
Study: NCT02980653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) 400 mg/day
Description: Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
Study: NCT01122953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epamin
Description: Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
Study: NCT02096224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Desflurane will be used
Study: NCT04508075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine (inactivated)
Description: SARS-CoV-2 vaccine (inactivated) manufactured by Sinovac

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo manufactured by PT. Bio Farma
Study: NCT04667169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Haemorrhoidal Artery Ligation
Description: Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Haemorrhoidoplasty
Description: Post-operatively, all subjects were given tablet Paracetamol 1 gm six hourly and Capsule Celecoxib 200 mg 12 hourly as pain control for five days. They were given Syrup Lactulose 15 cc 12 hourly for one week to prevent constipation. Subjects were discharged on the same day or one day after surgery. All patients were assessed in the clinic by a nurse/medical officer blinded to the type of procedure performed on post-operative 24 hours, one week and six weeks.
Study: NCT03678662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoalgesia expectation
Description: Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know about the effect of exercise on the experience of pressure pain is that after eg. cycling or walking, more pressure can be applied before the pressure starts to hurt and more pressure is required before you can't withstand anymore.~Whether this applies to a squat exercise, as the one you are about to perform, has not yet been investigated, but we expect that the same applies here, namely, that more pressure is required before you feel the pressure begins to hurt you and you will be able to endure a greater pressure.~Supported by visual information.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperalgesia expectation
Description: Before and after the squat exercise, assessment of how you experience pressure pain with the 2 devices you have just become acquainted with will be repeated. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.~What we currently know is that exercise can cause muscle pain, both during and after training. You may have experienced muscle soreness yourself in relation to training? We expect that the same will apply here. Namely, after performing this squat exercise, which will likely hurt your thigh muscles while doing it, you will experience that the pressure applied afterwards, with the two devices you have just become acquainted with, should be less before it starts to hurt and that you can endure less pressure.~Supported by visual information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral
Description: Soon you are going to do a training exercise in a squat position up against the wall for 3 min. Following the squat exercise, we will repeat the measurement of how you experience pressure pain with the 2 devices you have just become acquainted with. While doing the squat exercise you will be asked to indicate pain in the thigh muscles.